Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NextCell Pharma AB's revenue for the
three
months ended in Dec. 2025 was €0.16 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was €0.89 Mil.
NextCell Pharma AB's Revenue per Share for the
three
months ended in Dec. 2025 was €0.00.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.01.
Warning Sign:
NextCell Pharma AB revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of NextCell Pharma AB was -43.90% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 3.80% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 16.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 11 years, NextCell Pharma AB's highest 3-Year average Revenue per Share Growth Rate was 42.60% per year. The lowest was 3.80% per year. And the median was 26.70% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
NextCell Pharma AB Revenue Related Terms
NextCell Pharma AB Revenue Historical Data
* Premium members only.
The historical data trend for NextCell Pharma AB's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, NextCell Pharma AB's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NextCell Pharma AB Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NextCell Pharma AB's Revenue distribution charts can be found below:
* The bar in red indicates where NextCell Pharma AB's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.89 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NextCell Pharma AB (FRA:65G) has a Revenue of €0.89 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on NextCell Pharma AB and its competitors.
Is NextCell Pharma AB's Revenue too high?
NextCell Pharma AB's current Revenue is €0.89 Mil. Overall, NextCell Pharma AB has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NextCell Pharma AB's Revenue compare to VRTX and REGN?
NextCell Pharma AB's Revenue of €0.89 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on NextCell Pharma AB and its competitors. NextCell Pharma AB's current Revenue is €0.89 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NextCell Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, NextCell Pharma AB (FRA:65G) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.06, compared to a current price of €0.09 — trading 43.5% above its estimated fair value. The current Revenue is €0.89 Mil. NextCell Pharma AB's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For NextCell Pharma AB (FRA:65G), the current Revenue is €0.89 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NextCell Pharma AB (FRA:65G) Overvalued in 2026?
Based on GuruFocus' analysis, NextCell Pharma AB stock appears to be overvalued.
The current stock price of €0.09 is trading 43.5% above its estimated GF Value™ of €0.06.
GuruFocus considers NextCell Pharma AB to be Significantly Overvalued.
Key valuation signals for FRA:65G:
Revenue: €0.89 Mil
GF Value™: €0.06 vs. price of €0.09 (43.5% above fair value)
No single metric tells the full story. See the FRA:65G stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NextCell Pharma AB is a healthcare services provider. The company is engaged in the research of stem cell and is developing the candidate drug ProTrans for the treatment of diabetes and immunosuppression in kidney transplants.
42GF Score
Get the complete analysis for FRA:65G
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:65G has been successfully added to your 
